MichaelJohnAllinghamMDPhD

Ophthalmology • Durham, NC

Retinal Disease

Assistant Professor of Ophthalmology Duke Center for Macular Diseases Duke Eye Center

Join to view full profile

Dr. Allingham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Allingham's full profile

Already have an account?

Office
2301 Erwin Rd
Durham, NC 27705
Phone+1 919-684-8111

Education & Training

Duke University HospitalResidency, Ophthalmology, 2010 - 2013
Duke University HospitalInternship, Internal Medicine, 2009 - 2010
University of North Carolina at Chapel Hill School of MedicineClass of 2009

Certifications & Licensure

NC State Medical License 2013 - 2025
VA State Medical License 2013 - 2020
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Imaging Parameters and DME Treatment Response Start of enrollment: 2015 May 01
Completed

Publications & Presentations

PubMed

Association of Hyperautofluorescence Signals with Geographic Atrophy Progression in the METformin for the MINimization of Geographic Atrophy Progression Trial.
Abu Tahir Taha, Liangbo Linus Shen, Antonio Diaz, Noor Chahal, Jasmeet Saroya
Ophthalmology Science. 2024-09-12
3 citations
A Deep-Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on Spectral-Domain Optical Coherence Tomography.
Eliot R Dow, Hyeon Ki Jeong, Ella Arnon Katz, Cynthia A Toth, Dong Wang
JAMA Ophthalmology. 2023-11-01
1 citations
Fluorescein CorneoGraphy (FCG): Use of a repurposed fluorescein imaging technique to objectively standardize corneal staining.
Matias Soifer, Nadim S Azar, Ricardo Blanco, Hazem M Mousa, Seyyedehfatemeh Ghalibafan
The Ocular Surface. 2023-01-01

Press Mentions

Ocuphire Pharma : Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update - Form 8-KAugust 15th, 2022
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate UpdateMarch 24th, 2022
Duke Advanced Vitreous Surgery Course – 2018 HighlightsApril 15th, 2018